Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

She is being funded by MFF apparently -

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
XenaLives Member Profile
Member Level 
Followed By 318
Posts 40,995
Boards Moderated 30
Alias Born 09/20/01
160x600 placeholder
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 2/20/2020 4:32:14 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:38:56 PM
PURA ALERT - MACD Cross Pushing $0.039 50 Day MA With $0.35 Analyst TGT Recommendation InvestorsHub NewsWire - 2/10/2020 12:50:46 PM
PURA BUY Recommendation at $0.03 Issued By AmericanBulls InvestorsHub NewsWire - 2/7/2020 10:33:33 AM
Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates GlobeNewswire Inc. - 2/6/2020 7:00:10 AM
Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference GlobeNewswire Inc. - 2/4/2020 7:00:10 AM
Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Developmen... GlobeNewswire Inc. - 2/3/2020 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020 GlobeNewswire Inc. - 1/30/2020 7:00:10 AM
Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Dis... GlobeNewswire Inc. - 1/27/2020 7:00:10 AM
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 6:00:00 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
XenaLives Member Level  Saturday, 04/20/19 08:47:30 PM
Re: georgejjl post# 190079
Post # of 237780 
She is being funded by MFF apparently - historical post:


Quote:

I have no idea what is going on with this post. Mike is showing that Veronica Francardo, PhD will be presenting a poster at this year's MJFF Parkinson's Disease Therapeutics Conference this Oct. 30.

The grant was given to Nilsson, which really goes to the lab she oversees at Lund.

http://www.lunduniversity.lu.se/lucat/group/v1000356

Francardo most likely specializes in this type of research so Nilsson co-authors the paper with her as per the poster at the World Parkinson Congress 2016.

http://www.anavex.com/investigating-the-potential-neurorestorative-effects-of-a-clinical-sigma-1-receptor-agonist-in-a-mouse-model-of-parkinsons-disease/

Francardo is the lead author of the poster with Nilsson part of it as well and it shows that research was supported by the MJFF. And yes, MJFF is a partner with the World Parkinson Coalition that organizes that conference so I don't believe that Francardo will be presenting the exact same piece she did then.

These two have co-authored many papers over the years as well so I don't accept your assertion that because Francardo is presenting that it has nothing to do with MJFF grant given to Anavex and Nilsson.

http://portal.research.lu.se/portal/en/persons/veronica-francardo(9c206658-28b7-4a7c-a4e3-2f199ca7618a)/publications.html

I'm still waiting for your rebuttal as to IND's don't include trial design BTW.


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134048187

Quote:


polarbear77 Tuesday, 08/22/17 05:56:30 PM
Re: plexrec post# 116645 0
Post #
116646
of 190090
The Anavex train indeed Plex. Looks like they could be on track as well for Parkinson's trial readout in advance of Dr Francardo's presentation in May 2018 regarding a2-73 Parkinson's results.

Found her statements below to be fairly definitive and unambiguous re her testing to date. It seems the MJFF grant funds are being put to good use here.

GLTAL

Excerpted below from Dr Francardo [who is an independent researcher with grant funds from the Michael J. Foundation and has been studying the sigma-1 receptor for many years and publishing on the topic since at least 2011 (thanks again for pointing that out OFP)]:

"Using the same animal model of PD as in our previous study (i.e. intrastriatal 6-OHDA mouse model), we investigated the potential neurorestorative effects of ANAVEX 2-73, a compound with activity at both Sigma-1 and muscarinic receptors that is currently being tested in people affected by Alzheimer´s disease. Our results reveal that ANAVEX 2-73 is able to ameliorate parkinsonian motor symptoms in tests assessing spontaneous rotational activity and forelimb use asymmetry, and exerts neuroprotective/neurorestorative effects on the nigrostriatal dopamine system."

https://www.michaeljfox.org/foundation/researchers.php?id=1841
Veronica Francardo, PhD
Assistant Professor, Department of Experimental Medical Science BMC F11 at Lund University
Location: Lund, Sweden

Veronica Francardo received her undergraduate training at the University of Trieste, Italy, where she graduated in Medical Biotechnologies. Since 2007, Veronica is a researcher at Lund University, Sweden, where she obtained her PhD degree in Neurobiology under the supervision of Prof Angela Cenci-Nilsson. Veronica Francardo is currently Assistant Professor in the group of Prof. Angela Cenci-Nilsson and carries out pre-clinical research on animal models of Parkinson’s disease and post-mortem human brain tissue. The main interest of her work is to test and develop potential new therapies for Parkinson’s disease and related disorders."



https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134044839



In Peace, In War
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist